close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

18.45 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Amphastar (AMPH) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 CY2026 Sales Expectations, Stock Drops
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year at $171.2 ... 
Via StockStory
Topics Artificial Intelligence
Amphastar Pharmaceuticals (NASDAQ:AMPH) Q1 Results Miss Estimates, Stock Slides After Hours ↗
Via Chartmill
News headline image
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be announcing earnings results this Thursday after market hours. Here’s what investors sho... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Turn Down
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Plummets After Q4 Earnings Miss Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Why Amphastar Pharmaceuticals (AMPH) Shares Are Sliding Today
What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.7% in the afternoon session after Jefferies downgraded the stoc... 
Via StockStory
Topics Economy
News headline image
Amphastar Pharmaceuticals (AMPH): Buy, Sell, or Hold Post Q4 Earnings?
Over the last six months, Amphastar Pharmaceuticals’s shares have sunk to $22.73, producing a disappointing 6.3% loss - a stark contrast to the S&P 500’s 5.8... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ... 
Via StockStory
Topics Economy
News headline image
1 Healthcare Stock to Target This Week and 2 We Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have seen decent returns lat... 
Via StockStory
News headline image
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know
Via StockStory
Topics Economy
News headline image
Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH)
Looking back on generic pharmaceuticals stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amphastar Pharmaceuticals (NASDAQ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 15.8% in the afternoon session after the company reported fourth-quarter 2025 financial results that fell short of Wall... 
Via StockStory
Topics Economy
News headline image
Amphastar (AMPH) Q4 2025 Earnings Call Transcript ↗
Amphastar (AMPH) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Supply Chain
News headline image
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 1.8% year on year to $183.1 million. Its non-GAAP profit... 
Via StockStory
Topics Artificial Intelligence Supply Chain
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Value Stock on Our Watchlist and 2 We Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Topics Retirement
News headline image
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
3 Stocks Under $50 with Warning Signs
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.3% in the afternoon session after a Bank of America analyst lowered the firm's price target on the shares and reports... 
Via StockStory
News headline image
2 Reasons to Avoid AMPH and 1 Stock to Buy Instead
Amphastar Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.5%. The stock now trades at $27.76, marking a 31% gain. This was partly due to... 
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Profitable Stock Worth Your Attention and 2 Facing Headwinds
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered into an exclusive license agreement with Nanjing... 
Via StockStory
News headline image
3 Low-Volatility Stocks We Find Risky
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Amphastar Director Sells 16,679 Shares for $441,800 ↗
Amphastar is down big in 2025, but recently announced positive FDA-related news. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today